Synaptogenix announces plan to uplist on the nasdaq stock market

New york, may 19, 2021 /prnewswire/ -- synaptogenix, inc. (otc: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced that the company's board of directors has approved a one-for-four reverse stock split of its common stock effective prior to the opening of the market today, wednesday, may 19, 2021. the board of directors of synaptogenix determined this reverse stock split to be necessary in order for the company to fulfill the stock price requirements for official listing on the nasdaq stock market.
SNPX Ratings Summary
SNPX Quant Ranking